MedTrace Logo

Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia

NCT01672151 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2012-08-24

No results posted yet for this study

Summary

The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.

Conditions

  • Immune Thrombocytopenic Purpura

Interventions

DRUG

rapamycin

4mg oral administration on the first day, 2 mg/d oral administration for 3 months

Sponsors & Collaborators

  • First Affiliated Hospital of Suzhou Medical College

    lead OTHER

Principal Investigators

  • zhaoyue wang, doctor

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01672151 on ClinicalTrials.gov